title: New approaches to smoldering myeloma.
abstract: Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by the presence of one or both features of serum M-protein ≥ 30 g/L and bone marrow plasma cell infiltration ≥ 10 %. However, myeloma-related symptomatology is absent from this condition. The risk of progression to active MM is not uniform, and several markers are useful for identifying SMM patients at high risk of progression to active MM. These include the size of the M-protein and the infiltration in the bone marrow, the serum-free light-chain ratio, the presence of immunoparesis and percentage of plasma cell with aberrant phenotype by flow cytometry, or the presence of focal lesions in magnetic resonance imaging. Overall, the presence of these factors identifies patients who have a 50 % probability of progression at 2 years, and the forthcoming challenge will be to identify ultra-high-risk patients who have an 80 % risk of progression at 2 years. The current standard of care is not to treat until progression to symptomatic disease occurs. Several trials of melphalan, thalidomide and bisphosphonates have been conducted in the overall SMM patient population to examine the delay in time to progression (TTP) to symptomatic disease, but these have shown no significant benefit. However, a randomized trial that focused on high-risk SMM patients allocated to receive early treatment with lenalidomide plus dexamethasone versus observation did report a significant benefit with respect to TTP and overall survival. In summary, high-risk SMM patients should be targetted for early treatment, and more so efforts should be made to identify the ultra-high-risk subgroup within the high-risk SMM patient population which may be considered as early MM and thereby candidates for receiving therapy before they develop myeloma-related symptomatology.
authors: Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas, Salamanca, Spain, mvmateos@usal.es.
authors: María-Victoria
authors: MV
authors: Mateos
authors: Jesús F
authors: JF
authors: San Miguel
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D058070:Asymptomatic Diseases / Q000145:classification / Q000628:therapy*; D014408:Biomarkers, Tumor / Q000032:analysis; D018450:Disease Progression; D006801:Humans; D009101:Multiple Myeloma / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D011237:Predictive Value of Tests; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
references: Leukemia. 2013 Mar;27(3):680-5
references: 22902364
references: J Clin Oncol. 2010 Feb 1;28(4):690-7
references: 20026810
references: Leukemia. 2009 Jan;23(1):3-9
references: 18971951
references: Leuk Lymphoma. 2011 May;52(5):771-5
references: 21299465
references: Br J Haematol. 2003 Jun;121(5):749-57
references: 12780789
references: Blood. 2008 Jan 15;111(2):785-9
references: 17942755
references: J Clin Oncol. 1995 Jan;13(1):251-6
references: 7799027
references: Br J Cancer. 1996 May;73(9):1101-7
references: 8624271
references: J Clin Oncol. 2010 Mar 20;28(9):1606-10
references: 20177023
references: Eur J Haematol. 1993 Feb;50(2):95-102
references: 8440364
references: Br J Haematol. 2010 Jan;148(1):110-4
references: 19821821
references: Blood. 2008 Oct 15;112(8):3122-5
references: 18669874
references: Blood. 2007 Oct 1;110(7):2586-92
references: 17576818
references: N Engl J Med. 2013 Aug 1;369(5):438-47
references: 23902483
references: N Engl J Med. 1980 Jun 12;302(24):1347-9
references: 7374679
references: N Engl J Med. 2007 Jun 21;356(25):2582-90
references: 17582068
references: J Clin Oncol. 2003 Jan 1;21(1):16-9
references: 12506164
references: Br J Haematol. 2002 Jul;118(1):239-42
references: 12100153
references: Leukemia. 2013 Aug;27(8):1738-44
references: 23515097
references: Leukemia. 2013 Apr;27(4):941-6
references: 23183428
references: N Engl J Med. 2011 Aug 4;365(5):474-5
references: 21812699
references: Br J Cancer. 2000 Apr;82(7):1254-60
references: 10755397
references: Br J Haematol. 2003 Nov;123(4):631-6
references: 14616966
references: Cancer. 2008 Oct 1;113(7):1588-95
references: 18683218
references: Leukemia. 2003 Apr;17(4):775-9
references: 12682636
references: Leukemia. 2013 Jan;27(1):220-5
references: 22902362